B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC22A6

MOLECULAR TARGET

solute carrier family 22 member 6

UniProt: Q4U2R8NCBI Gene: 935622 compounds

SLC22A6 (solute carrier family 22 member 6) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC22A6

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1p-Aminohippuric Acid2.4811
2Probenecid2.309
3Dinoprostone1.393
4Indomethacin1.393
5Naproxen1.102
6Nateglinide1.102
7Thioctic Acid0.691
8Bumetanide0.691
9carbenicillin0.691
10cefadroxil0.691
11Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as0.691
12Cefazolin0.691
13Cefmetazole0.691
14Cefoperazone Semisynthetic broad-spectrum cephalosporin with0.691
15cefotaxime0.691
16Ceftriaxone0.691
17Cephaloridine0.691
18Dicloxacillin0.691
19Dinoprost0.691
20Furosemide0.691
21Glyburide0.691
22piperacillin0.691

About SLC22A6 as a Drug Target

SLC22A6 (solute carrier family 22 member 6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented SLC22A6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC22A6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.